The Ritedose Corporation

FDA Approves Ritedose's Albuterol Sulfate Inhalation Solution Amid National Shortage

• Ritedose Pharmaceuticals has received FDA approval for Albuterol Sulfate Inhalation Solution 0.5% (2.5 mg/0.5 mL), completing their portfolio of albuterol treatments amid a nationwide shortage that has persisted since October 2022. • The newly approved dosage will be manufactured using Blow-Fill-Seal technology in Ritedose's expanded facilities, with availability expected in the second quarter of 2025 to help address critical needs for over 26 million asthma patients. • This approval strengthens Ritedose's position as the largest provider of nebulizer products in the US, having delivered more than 4.5 billion doses throughout the company's history.